Xconomy
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals |  |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
News, Syndication, Xconomy »
Lighting the Way to Better Understanding of the Brain | |
|
Posted by sandiegobiotech April 10th, 2013 .
| |
| No Comments |
We are enamored by our brains. Arguably the most complex system in the universe that is made up of over 80 billion neurons, the brain is a complex organ that can be a source of marvel and…
[[Click headline to continue reading.]]
More...News, Syndication, Xconomy »
Roche & Isis Join Forces on Antisense Drug for Huntington’s Disease | |
|
Posted by sandiegobiotech April 8th, 2013 .
| |
| No Comments |
San Diego’s Isis Pharmaceuticals (NASDAQ: ISIS) and Roche, the Swiss Pharmaceuticals giant) have formed an alliance to develop new treatments for Huntington’s disease, according to a statement…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
San Diego’s Ambrx Working with Astellas to Develop Anti-Cancer Drugs | |
|
Posted by sandiegobiotech April 8th, 2013 .
| |
| No Comments |
San Diego-based Ambrx says it’s getting an upfront payment of $15 million under a deal with Japan’s Astellas to help develop an undisclosed number of targets for antibody drug conjugates in cancer….
[[Click headline to continue reading.]]
News, Syndication, Xconomy »
The Brain Map Shouldn’t Get $100M a Year. It Should Get Much More | |
|
Posted by sandiegobiotech April 8th, 2013 .
| |
| No Comments |
The human brain, as Francis Collins recently said, “is the most complicated organ in the universe.” We only have vague ideas today of how it works at the level of genes, and neural circuits. Deeper…
[[Click headline to continue reading.]]
News, Syndication, Xconomy »
SEC’s New Social Media Guidance: Sensible, Fair, Inevitable | |
|
Posted by sandiegobiotech April 2nd, 2013 .
| |
| No Comments |
Give the SEC a lot of credit…the headline they chose for their press release yesterday about public companies using social media could not have been more clear: “SEC Says Social Media OK for Company…
[[Click headline to continue reading.]]
News, Syndication, Xconomy »
Gilead Sciences Building on HIV, Becoming Cancer Drug Force | |
|
Posted by sandiegobiotech April 1st, 2013 .
| |
| No Comments |
Gilead Sciences has had what you could call a “high-class problem” the last few years. Biotech companies that are great at one thing eventually must prove they can be great at something else. And…
[[Click headline to continue reading.]]
